Assignee
CULLGEN SHANGHAI INC
CN·3 granted patents·15 pending applications·3 citations·filing 2019–2025
Top patents by PatentIndex Score
18 records- 0185US12065442B2Tropomyosin receptor kinase (TRK) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2019·Granted Aug 20, 2024·2 cites·6 claims
- 0280US12410171B2Tropomyosin receptor kinase (TRK) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2021·Granted Sep 9, 2025·1 cites·12 claims
- 0378US2025388587A1Tropomyosin receptor kinase (trk) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2025·Application pending·0 cites
- 0476US2024400570A1Tropomyosin receptor kinase (trk) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2024·Application pending·0 cites
- 0569US2024066136A1Modified proteins and protein degradersCULLGEN SHANGHAI INC·Filed 2023·Application pending·0 cites
- 0664US2025325678A1Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2025·Application pending·0 cites
- 0762US2023057177A1Modified proteins and protein degradersCULLGEN SHANGHAI INC·Filed 2021·Application pending·0 cites
- 0858US2024335452A1Compositions and methods of combination therapy for targeting lymphomaCULLGEN SHANGHAI INC·Filed 2022·Application pending·0 cites
- 0958US2025221988A1Compounds and methods of treating cancersCULLGEN SHANGHAI INC·Filed 2023·Application pending·0 cites
- 1056US2025235543A1Modified proteins and protein degradersCULLGEN SHANGHAI INC·Filed 2022·Application pending·0 cites
- 1154US2024197694A1Modified proteins and protein bindersCULLGEN SHANGHAI INC·Filed 2022·Application pending·0 cites
- 1254US2023073777A1Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2020·Application pending·0 cites
- 1353US2024050428A1Compounds and methods of treating cancersCULLGEN SHANGHAI INC·Filed 2021·Application pending·0 cites
- 1453US2024100170A1Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2021·Application pending·0 cites
- 1552US11969472B2Tropomyosin receptor kinase (TRK) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2021·Granted Apr 30, 2024·0 cites·11 claims
- 1652US2024246955A1Tropomyosin receptor kinase (trk) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2022·Application pending·0 cites
- 1752US2024059671A1Tyrosine kinase 2 (tyk2) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2021·Application pending·0 cites
- 1846US2023093099A1Compounds and methods of treating cancersCULLGEN SHANGHAI INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when CULLGEN SHANGHAI INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →